KR20090101581A - The preparaton of alkenylazetidinone intermediates for carbapenems - Google Patents

The preparaton of alkenylazetidinone intermediates for carbapenems

Info

Publication number
KR20090101581A
KR20090101581A KR1020080026799A KR20080026799A KR20090101581A KR 20090101581 A KR20090101581 A KR 20090101581A KR 1020080026799 A KR1020080026799 A KR 1020080026799A KR 20080026799 A KR20080026799 A KR 20080026799A KR 20090101581 A KR20090101581 A KR 20090101581A
Authority
KR
South Korea
Prior art keywords
ether
amino
azetidinone
naphthol
incl
Prior art date
Application number
KR1020080026799A
Other languages
Korean (ko)
Other versions
KR100969217B1 (en
Inventor
김성훈
강석원
안현주
김혜란
김용훈
Original Assignee
건국대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 건국대학교 산학협력단 filed Critical 건국대학교 산학협력단
Priority to KR1020080026799A priority Critical patent/KR100969217B1/en
Publication of KR20090101581A publication Critical patent/KR20090101581A/en
Application granted granted Critical
Publication of KR100969217B1 publication Critical patent/KR100969217B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PURPOSE: A method for preparing an alkenyl azetidinone intermediate for carbapenem is provided to easily synthesize effective 1β-methyl carbapenem compound with low price. CONSTITUTION: A method for preparing an alkenyl azetidinone intermediate for carbapenem comprises: a step of preparation with 4(R)-acetoxyazetidinone as a starting material; a step of performing crotylation under the presence of chiral ligand, transition metal, and Lewis acid; and a step of producing 4-(alk-2-enyl)-2-azetidinone of the chemical formula 1. The chiral ligand is selected from cinchonine, cinchonidin, quinine, quinidine, norephedrin, O-acetylquinine, and O-acetylquinidine. The transition metal is selected from zinc or indium. The Lewis acid is selected from AgCl, PdCl, AgOTf, InCl3, ZnBr2, and Sc(OTf)3.

Description

카르바페넴을 위한 알케닐 아제티디논 중간체 제조방법 {THE PREPARATON OF ALKENYLAZETIDINONE INTERMEDIATES FOR CARBAPENEMS}Preparation of alkenyl azetidinone intermediates for carbapenems {THE PREPARATON OF ALKENYLAZETIDINONE INTERMEDIATES FOR CARBAPENEMS}

본 발명은 카르바페넴을 위한 알케닐 아제티디논 중간체 제조방법에 관한 것으로, 더욱 상세하게는 하기 화학식 1로 표현되며, 카르바페넴-타입 항생제의 중간체로 사용되는 1β-메틸 카르바페넴을 제조하기 위한 아제티디논 유도체인 4-(알크-2-에닐)-2-아제티디논 의 제조방법에 관한 것이다. The present invention relates to a method for preparing alkenyl azetidinone intermediates for carbapenem, more specifically, represented by the following formula (1), to prepare 1β-methyl carbapenem used as an intermediate of carbapenem-type antibiotics It relates to a method for preparing 4- (alk-2-enyl) -2-azetidinone which is an azetidinone derivative.

단, 상기에서 R1, R2 는 각각 H, Me 이고, R3 는 수소원자 또는 하이드록실-보호 그룹이다.Provided that R 1 and R 2 are each H and Me, and R 3 is a hydrogen atom or a hydroxyl-protecting group.

카르바페넴-타입 항균제는 그램-양성 박테리아로부터 슈도모나스아에루기노사 (Pseudomonas aeruginosa)를 포함하는 그램-음성 박테리아에 이르는 박테리아의 광범위한 스펙트럼에 대해 강한 항균활성을 갖는 탁월한 항균제로, 최근 카르바페넴-타입의 신규한 항균제가 활발하게 개발되고 있다.Carbapenem-type antimicrobials are excellent antimicrobial agents that have strong antimicrobial activity against a broad spectrum of bacteria, from Gram-positive bacteria to Gram-negative bacteria, including Pseudomonas aeruginosa . Types of new antibacterial agents are being actively developed.

카르바페넴 화합물은 통상 하기 화학식 2의 티에나마이신과 같은 카바페넴 골격를 갖는다. Carbapenem compounds usually have a carbapenem skeleton, such as thienamycin of formula (2).

그러나, 1번 위치에 치환체가 없는 카르바페넴 항균제는 화학적으로 불안정하며, 더욱이 생체 내에서는 데하이드로펩티다아제(Dehydropeptidase) 1에 의해 쉽게 대사되는 단점이 있다 (Antimicrob. Agents Chemother. 1982, 22, 62.; J. Antibiotics 1979, 32, 1.).However, carbapenem antimicrobials without substituents at position 1 are chemically unstable and, furthermore, are easily metabolized by Dehydropeptidase 1 in vivo ( Antimicrob. Agents Chemother. 1982, 22, 62. ; J. Antibiotics 1979, 32, 1.).

이를 해결하기 위해, 1번 위치에 베타-배위의 알킬 그룹을 혼입시키면 이러한 카르바페넴 유도체의 안정성이 향상되고 이들 유도체들을 데하이드로펩티다아제 억제제를 가할 필요 없이 단독으로 사용할 수 있다. 그 결과, 입체화학적으로 매우 순수한 카르바페넴으로 전환될 수 있다. To solve this problem, incorporation of beta-coordinated alkyl groups into position 1 improves the stability of these carbapenem derivatives and these derivatives can be used alone without the need to add a dehydropeptidase inhibitor. As a result, it can be converted to stereochemically very pure carbapenems.

종래, 1β-메틸 카르바페넴을 합성하기 위한 출발물질인 4-(알크-2-에닐)-2-아제티디논을 제조하는 방법은 비입체특이적이고 (J. Org. Chem., 50, 3438, 1985), 생성물의 입체 화학은 조절될 수 없어서 공정의 불충분한 실시가능성을 초래하여 목적하는 1β-메틸 카르바페넴의 수득률이 낮다는데 문제가 있다.Conventionally, the method for preparing 4- (alk-2-enyl) -2-azetidinone, which is a starting material for synthesizing 1β-methyl carbapenem, is non-stereospecific ( J. Org. Chem. , 50, 3438 , 1985), the steric chemistry of the product cannot be controlled, resulting in insufficient feasibility of the process, resulting in a low yield of the desired 1β-methyl carbapenem.

다시 말해, 다양한 치환기를 갖는 1β-메틸카르바페넴-타입 유도체의 R- 및 S- 이성질체는 각각 1 : 1의 비율로 수득되어 유용성이 적은 R- 이성질체 또는 적어도 상당량의 R- 이성질체와의 혼합물로 제조되므로 (Chem. Pharm. Bull., 39(3), 663-671, 1991), 이로부터 목적하는 S- 이성질체를 분리하는 것은 어렵고, 비용이 많이 들며 비효율적이었다.In other words, the R- and S-isomers of the 1β-methylcarbapenem-type derivatives having various substituents are obtained in a ratio of 1: 1, respectively, in a mixture with less useful R- isomers or at least a substantial amount of R- isomers. As prepared ( Chem. Pharm. Bull. , 39 (3), 663-671, 1991), it was difficult, costly and inefficient to separate the desired S-isomer from it.

이에 본 발명자들은 원하는 화합물을 더욱 양호한 수율로 수득할 수 있도록 목적 이성질체를 주생성물로 하는 4-(알크-2-에닐)-2-아제티디논, 즉 (4R)-4-[(1S)-1-메틸알릴]-2-아제티디논{(4R)-4-[(1S)-1-Methylallyl]-2-azetidinone} 을 제조하기 위해 예의 노력한 결과, 목적하는 이성질체를 기존 보다 최고 3배 이상 수득할 수 있음을 확인하고 본 발명을 완성하였다.Thus, the present inventors used 4- (alk-2-enyl) -2-azetidinone, i.e., (4R) -4-[(1S)-, with the target isomer as the main product so that the desired compound can be obtained in better yield. As a result of intensive efforts to prepare 1-methylallyl] -2-azetidinone {(4R) -4-[(1S) -1-Methylallyl] -2-azetidinone}, the desired isomer is up to three times higher than before. It was confirmed that it can be obtained and completed the present invention.

결국, 본 발명의 주된 목적은 항균성의 1β-메틸 카르바페넴을 제조하기 위한 주요 중간체인 4-(알크-2-에닐)-2-아제티디논의 목적하는 이성질체를 고수율로 제조하는 입체 특이적 방법을 제공하는데 있다. After all, the main object of the present invention is stereospecific for preparing the desired isomer of 4- (alk-2-enyl) -2-azetidinone, which is the main intermediate for preparing antimicrobial 1β-methyl carbapenem. To provide a method.

상기 목적을 달성하기 위해, 본 발명은 4-아세톡시아제티디논 (4(R)-acetoxyazetidinone, Ⅰ)을 출발물질로 하고, 키랄 리간드(Chiral Ligand), 전이금속, 루이스 산(Lewis acid)의 존재 하에서 크로틸화(crotylation) 시키는 것을 특징으로 하는 베타형(β-form)의 4-(알크-2-에닐)-2-아제티디논(Ⅱ, 화학식 1)의 제조방법을 제공한다.In order to achieve the above object, the present invention uses 4-acetoxyazetidinone (4 (R) -acetoxyazetidinone (I)) as a starting material, chiral ligand (Chiral Ligand), transition metal, Lewis acid (Lewis acid) It provides a method for the preparation of beta (β-form) 4- (alk-2-enyl) -2-azetidinone (II, Formula 1) characterized in that it is crotylation in the presence.

본 발명에 있어서, 상기 키랄 리간드는 신코닌(cinchonine), 신코니딘(cinchonidin), 퀴닌(quinine), 퀴니딘(quinidine), 노르에페드린(norephedrin), 2,2'-비스(디페닐포스피노)-1,1'-비나프틸(BINAP), (S)-(-)-아미노-3-페닐-1-프로판올{(S)-(-)-Amino-3-phenyl-1-propanol}, (R)-(-)-2-페닐글리시놀{(R)-(-)-2-Phenylglycinol}, 아미노-2-인단올(Amino-2-indanol), (S)-(+)-2-아미노-1-부탄올{(S)-(+)-Amino-1-butanol}, O-아세틸신코닌(O-acetylcinchonine), O-아세틸신코니딘(O-acetylcinchonidine), (R)-바이(2-나프톨){(R)-Bi(2-naphthol)}, (S)-바이(2-나프톨){(S)-Bi(2-naphthol)}, S-2-아미노프로판올(S-2-Aminopropanol), R-2-아미노프로판올(R-2-Aminopropanol), O-아세틸퀴닌(O-acetylquinine), O-아세틸퀴니딘(O-acetylquinidine)으로 이루어진 군에서 선택되는 것을 특징으로 하며, 상기 전이금속은 아연(Zn) 또는 인듐(In)인 것을 특징으로 할 수 있다.In the present invention, the chiral ligand is cinchonine, cinchonidin, quinine, quinine, quinidine, norephedrin, 2,2'-bis (diphenylphosphino) ) -1,1'-binafyl (BINAP), (S)-(-)-amino-3-phenyl-1-propanol {(S)-(-)-Amino-3-phenyl-1-propanol} , (R)-(-)-2-phenylglycinol {(R)-(-)-2-Phenylglycinol}, amino-2-indanol, (S)-(+) -2-amino-1-butanol {(S)-(+)-Amino-1-butanol}, O-acetylcinchonine, O-acetylcinchonidine, (R) -Bi (2-naphthol) {(R) -Bi (2-naphthol)}, (S) -bi (2-naphthol) {(S) -Bi (2-naphthol)}, S-2-aminopropanol ( S-2-Aminopropanol), R-2-aminopropanol (R-2-Aminopropanol), O-acetylquinine (O-acetylquinine), O-acetylquinidine (O-acetylquinidine) characterized in that it is selected from the group consisting of In addition, the transition metal may be characterized in that the zinc (Zn) or indium (In).

또한, 본 발명에 있어서, 상기 루이스 산은 AgCl, PdCl, AgOTf, CuCl, CuCN, Cu(OAc)2, InCl3, PbBr2, GaCl3, Ti(OPr)4, CeCl3, Sc(OTf)3, ZnCl2, ZnBr2 로 이루어진 군에서 선택되는 것이 특징이고, 반응용매로는 석유에테르, 이소프로필에테르(IPE), 디에틸에테르, 디부틸에테르, t-부틸메틸에테르, 디옥산 등의 에테르(Ether) 용매; 테트라히드로퓨란(THF), 디알콕시알칸, N,N-디메틸 포름아마이드(N,N-Dimethyl foramide, DMF), 디메틸아세트아마이드, 디메틸술폰아마이드, 디클로로메탄(Dichloromethane, MC), 아세토니트릴(MeCN) 등의 극성용매; 벤젠, 톨루엔 등의 방향족 용매;로 이루어진 군에서 선택되는 1종 이상을 단독 또는 병행하여 사용하는 것을 특징으로 한다.In addition, in the present invention, the Lewis acid is AgCl, PdCl, AgOTf, CuCl, CuCN, Cu (OAc) 2 , InCl 3 , PbBr 2 , GaCl 3 , Ti (OPr) 4, CeCl 3 , Sc (OTf) 3, It is characterized in that it is selected from the group consisting of ZnCl 2 , ZnBr 2 , and the reaction solvent is an ether such as petroleum ether, isopropyl ether (IPE), diethyl ether, dibutyl ether, t-butyl methyl ether, dioxane ) Solvents; Tetrahydrofuran (THF), dialkoxyalkane, N, N-dimethyl foramide (DMF), dimethylacetamide, dimethylsulfonamide, dichloromethane (MC), acetonitrile (MeCN) Polar solvents such as these; It is characterized by using one or more types selected from the group consisting of aromatic solvents such as benzene and toluene alone or in parallel.

본 발명에 따른 제조방법은, 원하는 광학 이성질체를 기존 보다 최고 3배 이상 고수율로 수득하는 것이 가능할 뿐만 아니라, 카르바페넴 항생제의 중간체로 사용되는 1β-메틸 카르바페넴을 제조하기 위한 중요한 중간체인 아제티디논 유도체, 즉 베타형의 4-(알크-2-에닐)-2-아제티디논(화학식 1)을 제공함으로써, 유효한 1β-메틸 카르바페넴 화합물의 합성을 비교적 용이하게 저비용으로 제조하는 것이 가능하여 산업화에 유용하게 이용될 수 있다.The preparation method according to the invention is not only possible to obtain the desired optical isomer in a high yield up to three times higher than conventionally, but also is an important intermediate for preparing 1β-methyl carbapenem used as an intermediate of carbapenem antibiotics. By providing an azetidinone derivative, i.e., the beta form 4- (alk-2-enyl) -2-azetidinone (Formula 1), the synthesis of an effective 1β-methyl carbapenem compound is relatively easy and at low cost. It is possible to be usefully used for industrialization.

이하, 본 발명을 상세하게 설명한다.EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated in detail.

본 발명은 4-아세톡시아제티디논(4(R)-acetoxyazetidinone, Ⅰ)을 출발물질로 하고, 키랄 리간드(Chiral Ligand), 전이금속, 루이스 산(Lewis acid)의 존재 하에서 크로틸화(crotylation) 시켜 상기 화학식 1로 표현되는 4-(알크-2-에닐)-2-아제티디논(Ⅱ)을 제조하는 방법을 제공한다.The present invention uses 4-acetoxyazetidinone (4 (R) -acetoxyazetidinone (I) as a starting material, and crotylation in the presence of chiral ligands, transition metals and Lewis acids. To provide 4- (alk-2-enyl) -2-azetidinone (II) represented by Chemical Formula 1 above.

본 발명의 바람직한 실시양태는 하기와 같이 나타낼 수 있다.Preferred embodiments of the present invention can be represented as follows.

단, 상기에서 R 은 수소원자 또는 하이드록실-보호 그룹으로, 특히 TBDMS(t-부틸디메틸실릴기)인 것이 바람직하다. However, in the above, R is a hydrogen atom or a hydroxyl-protecting group, particularly preferably TBDMS (t-butyldimethylsilyl group).

본 발명에 있어서, 상기 키랄리간드는 신코닌(cinchonine), 신코니딘(cinchonidin), 퀴닌(quinine), 퀴니딘(quinidine), 노르에페드린(norephedrin), 2,2'-비스(디페닐포스피노)-1,1'-비나프틸(BINAP), (S)-(-)-아미노-3-페닐-1-프로판올{(S)-(-)-Amino-3-phenyl-1-propanol}, (R)-(-)-2-페닐글리시놀{(R)-(-)-2-Phenylglycinol}, 아미노-2-인단올(Amino-2-indanol), (S)-(+)-2-아미노-1-부탄올{(S)-(+)-Amino-1-butanol}, O-아세틸신코닌(O-acetylcinchonine), O-아세틸신코니딘(O-acetylcinchonidine), (R)-바이(2-나프톨){(R)-Bi(2-naphthol)}, (S)-바이(2-나프톨){(S)-Bi(2-naphthol)}, S-2-아미노프로판올(S-2-Aminopropanol), R-2-아미노프로판올(R-2-Aminopropanol), O-아세틸퀴닌(O-acetylquinine), O-아세틸퀴니딘(O-acetylquinidine)으로 이루어진 군에서 선택되는 것이 바람직하며, 상기 전이금속은 아연(Zn) 또는 인듐(In)인 것이 바람직하다.In the present invention, the chiral ligand is cinchonine (cinchonine), cinchonidin (cinchonidin), quinine (quinine), quinidine (quinidine), norephedrin (norephedrin), 2,2'-bis (diphenylphosphino ) -1,1'-binafyl (BINAP), (S)-(-)-amino-3-phenyl-1-propanol {(S)-(-)-Amino-3-phenyl-1-propanol} , (R)-(-)-2-phenylglycinol {(R)-(-)-2-Phenylglycinol}, amino-2-indanol, (S)-(+) -2-amino-1-butanol {(S)-(+)-Amino-1-butanol}, O-acetylcinchonine, O-acetylcinchonidine, (R) -Bi (2-naphthol) {(R) -Bi (2-naphthol)}, (S) -bi (2-naphthol) {(S) -Bi (2-naphthol)}, S-2-aminopropanol ( S-2-Aminopropanol), R-2-Aminopropanol, O-acetylquinine (O-acetylquinine), O-acetylquinidine (O-acetylquinidine) is preferably selected from the group consisting of , The transition metal is preferably zinc (Zn) or indium (In).

또한, 본 발명에 있어서, 상기 루이스산은 AgCl, PdCl, AgOTf, CuCl, CuCN, Cu(OAc)2, InCl3, PbBr2, GaCl3, Ti(OPr)4, ZnCl2, ZnBr2,CeCl3, Sc(OTf)3 로 이루어진 군에서 선택되는 것이 바람직하다.In addition, in the present invention, the Lewis acid is AgCl, PdCl, AgOTf, CuCl, CuCN, Cu (OAc) 2 , InCl 3 , PbBr 2 , GaCl 3 , Ti (OPr) 4, ZnCl 2 , ZnBr 2 , CeCl 3 , It is preferably selected from the group consisting of Sc (OTf) 3 .

또한, 본 발명에 있어서, 반응용매로는 석유에테르, 이소프로필에테르(IPE), 디에틸에테르, 디부틸에테르, t-부틸메틸에테르, 디옥산 등의 에테르(Ether) 용매; 테트라히드로퓨란(THF), 디알콕시알칸, N,N-디메틸 포름아마이드(N,N-Dimethyl foramide, DMF), 디메틸아세트아마이드, 디메틸술폰아마이드, 디클로로메탄(Dichloromethane, MC), 아세토니트릴(MeCN) 등의 극성용매; 벤젠, 톨루엔 등의 방향족 용매;로 이루어진 군에서 선택되는 1종 이상을 단독 또는 병행하여 사용할 수 있는데, 특히 디에틸에테르, THF, DMF, MC, MeCN로 이루어진 군에서 선택되는 1종 이상인 것이 바람직하다.In the present invention, the reaction solvent may be an ether solvent such as petroleum ether, isopropyl ether (IPE), diethyl ether, dibutyl ether, t-butyl methyl ether, dioxane; Tetrahydrofuran (THF), dialkoxyalkanes, N, N-dimethyl foramide (DMF), dimethylacetamide, dimethylsulfonamide, dichloromethane (MC), acetonitrile (MeCN) Polar solvents such as these; At least one selected from the group consisting of aromatic solvents such as benzene and toluene; may be used alone or in combination. Particularly, at least one selected from the group consisting of diethyl ether, THF, DMF, MC, and MeCN is preferable. .

또한, 본 발명에 있어서, 상기에서 키랄 리간드는 0.005 ~ 3 당량, 바람직하게는 0.025 ~ 1 당량 첨가되는 것이 좋고, 상기 루이스 산은 0.005 ~ 3 당량, 바람직하게는 0.025 ~ 1 당량 첨가되는 것이 좋으며, 반응 온도범위는 0 ~ 50℃, 바람직하게는 0 ~ 35℃인 것이 좋다. In the present invention, the chiral ligand is preferably added in an amount of 0.005 to 3 equivalents, preferably 0.025 to 1 equivalent, and the Lewis acid is preferably added in an amount of 0.005 to 3 equivalents, preferably 0.025 to 1 equivalent, The temperature range is 0 to 50 ° C, preferably 0 to 35 ° C.

이하, 실시 예에 의하여 본 발명을 더욱 상세히 설명하고자 한다.Hereinafter, the present invention will be described in more detail with reference to Examples.

단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시 예에 한정되는 것은 아니다. However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.

실시예Example 1. 4-(R)-[1- 4- (R)-[1- methylmethyl (( allylallyl )-)- azetidinoneazetidinone ]의 제조 Ⅰ Manufacture of I

글로브 박스에서 둥근 바닥 플라스크에 4-아세톡시아제티디논(4(R)-acetoxyasetidinone, AOSA) 0.1 g(0.34 mmol), 신코닌 0.044 g(0.5 당량), 염화인듐 0.033 g(0.5 당량)를 넣고 아르곤 기체를 채워 밀봉하였다. 여기에 에테르 5 ㎖를 투입하여 반응온도를 25 ~ 35℃으로 유지하면서 크로틸 브롬 0.081 g(2.0 당량)를 천천히 가하고, 30분 후에 아연 0.04 g(2.0 당량)를 첨가한 후 29℃에서 총 4시간에 걸쳐 교반하되, 반응의 진행여부는 TLC(ether : n-hexane = 2 : 1)로 확인하였다. 상기 반응물에 다시 포화 염화암모늄 용액 10 ㎖ 및 에테르 20 ㎖를 가하고 2 ~ 3분 동안 교반한 다음, 분별 깔때기를 사용하여 물층을 제거하였다. 물층을 제거한 유기층에 무수 소듐 셀페이트를 2 ~ 3 g 투입하고 15분간 교반하여 유기층 속에 남아있는 물층을 완전하게 제거한 후 글래스 필터로 여과하고 유기용매(에테르)로 세척하여 유기층을 감압 농축하였다. In a glove box, add 0.1 g (0.34 mmol) of 4-acetoxyasetidinone (4 (R) -acetoxyasetidinone (AOSA)), 0.044 g (0.5 equiv) of cinconine, and 0.033 g (0.5 equiv) of indium chloride in a round bottom flask. Sealed with argon gas. 5 ml of ether was added thereto, and 0.081 g (2.0 equivalents) of crotyl bromide was slowly added while maintaining the reaction temperature at 25 to 35 ° C. After 30 minutes, 0.04 g (2.0 equivalents) of zinc was added, followed by a total of 4 at 29 ° C. Stirring over time, the progress of the reaction was confirmed by TLC (ether: n-hexane = 2: 1). 10 ml of saturated ammonium chloride solution and 20 ml of ether were added to the reaction mixture, stirred for 2-3 minutes, and then the water layer was removed using a separatory funnel. 2-3 g of anhydrous sodium sulfate was added to the organic layer from which the water layer was removed, followed by stirring for 15 minutes to completely remove the remaining water layer in the organic layer, followed by filtration with a glass filter, washing with an organic solvent (ether), and concentrating the organic layer under reduced pressure.

상기와 같은 과정으로 베타형 : 알파형의 비율이 2.5 : 1인 흰색의 4(R)-[1-methyl(allyl)-azetidinone]을 결정 형태로 93 ㎎(수득율 95%)을 수득하였다. As described above, 93 mg (yield 95%) of white 4 (R)-[1-methyl (allyl) -azetidinone] having a beta-type alpha ratio of 2.5: 1 was obtained in crystalline form.

(1) 베타형(β-form)(1) beta form (β-form)

1H-NMR (400MHz, CDCl3): 0.02~0.09(6H), 0.83~0.94(9H), 1.03~1.07(3H), 1.12~1.18(3H), 1.22~1.34(3H), 2.25~2.34(1H), 2.79~2.80(1H), 3.46~3.48(1H), 4.13~4.23(1H), 5.02~5.13(2H), 5.68~5.81(1H), 6.51(1H) 1 H-NMR (400 MHz, CDCl 3 ): 0.02 to 0.09 (6H), 0.83 to 0.94 (9H), 1.03 to 1.07 (3H), 1.12 to 1.18 (3H), 1.22 to 1.34 (3H), 2.25 to 2.24 ( 1H), 2.79-2.80 (1H), 3.46-3.48 (1H), 4.13-4.23 (1H), 5.02-5.13 (2H), 5.68-5.81 (1H), 6.51 (1H)

(2) 알파형(α-form)(2) alpha-form

1H-NMR (400MHz, CDCl3): 0.02~0.09(6H), 0.83~0.94(9H), 1.03~1.07(3H), 1.12~1.18(3H), 1.22~1.34(3H), 2.19~2.24(1H), 2.75~2.77(1H), 3.38~3.40(1H), 4.13~4.23(1H), 5.02~5.13(2H), 5.61~5.70(1H), 6.29(1H) 1 H-NMR (400 MHz, CDCl 3 ): 0.02 to 0.09 (6H), 0.83 to 0.94 (9H), 1.03 to 1.07 (3H), 1.12 to 1.18 (3H), 1.22 to 1.34 (3H), 2.19 to 2.24 ( 1H), 2.75-2.77 (1H), 3.38-3.40 (1H), 4.13-4.23 (1H), 5.02-5.13 (2H), 5.61-5.70 (1H), 6.29 (1H)

실시예 2. 4-(R)-[1-methyl(allyl)-azetidinone]의 제조 Ⅱ Example 2. Preparation of 4- (R)-[1-methyl (allyl) -azetidinone] II

상기 실시예 1과 동일한 방법으로 제조하되, 에테르 2.5 ㎖와 아연을 동시에 첨가하여 제조하고, 베타형 : 알파형의 비율이 2.0 : 1인 흰색의 4(R)-[1-methyl(allyl)-azetidinone]을 결정 형태로 수득하였다(수득율 95%). Prepared in the same manner as in Example 1, but was prepared by adding 2.5 ml of ether and zinc at the same time, the beta form of the alpha form ratio of 2.0: 1 4 (R)-[1-methyl (allyl)- azetidinone] was obtained in crystalline form (yield 95%).

실시예 3 ~ 26. 4-(R)-[1-methyl(allyl)-azetidinone]의 제조 Ⅲ Examples 3 to 26. Preparation of 4- (R)-[1-methyl (allyl) -azetidinone] III.

출발물질로서 0.3 mmol의 ASOA를 사용하여 상기 실시예 2와 동일한 방법으로 제조하고, 이때 사용한 키랄 리간드, 루이스산, 전이금속 및 용매는 하기의 표 1에 수득 비율과 함께 나타내었다. Using 0.3 mmol of ASOA as a starting material, the preparation was carried out in the same manner as in Example 2, and the chiral ligand, Lewis acid, transition metal, and solvent used were shown in Table 1 below with the obtained ratios.

실시예Example 키랄 리간드Chiral ligand 당량(eq.)Equivalent (eq.) 루이스산Lewis Mountain 당량(eq.)Equivalent (eq.) 용매menstruum 전이금속Transition metal 비율(β:α)Ratio (β: α) 33 cinchoninecinchonine 0.50.5 InCl3 InCl 3 0.10.1 EtherEther ZnZn 2.1 : 1.02.1: 1.0 44 cinchoninecinchonine 1One AgClAgCl 0.10.1 THFTHF ZnZn 2.0 : 1.02.0: 1.0 55 cinchonidinecinchonidine 0.50.5 InCl3 InCl 3 0.50.5 EtherEther ZnZn 1.6 : 1.01.6: 1.0 66 cinchoninecinchonine 0.50.5 AgOTfAgOTf 0.50.5 THFTHF InIn 1.78 : 1.01.78: 1.0 77 cinchoninecinchonine 0.50.5 InCl3 InCl 3 0.50.5 DMFDMF ZnZn 1.4 : 1.01.4: 1.0 88 cinchoninecinchonine 1One InCl3 InCl 3 1One EtherEther ZnZn 1.7 : 1.01.7: 1.0 99 cinchoninecinchonine 0.50.5 InCl3 InCl 3 0.50.5 DMFDMF ZnZn 1.2 : 1.01.2: 1.0 1010 cinchonidinecinchonidine 0.50.5 InCl3 InCl 3 0.50.5 DMFDMF ZnZn 1.2 : 1.01.2: 1.0 1111 cinchoninecinchonine 0.50.5 InCl3 InCl 3 1One EtherEther ZnZn 1.5 : 1.01.5: 1.0 1212 QuinidineQuinidine 0.50.5 InCl3 InCl 3 0.50.5 EtherEther ZnZn 1.8 : 1.01.8: 1.0 1313 (S)-(-)-Amino-3-phenyl-1-propanol(S)-(-)-Amino-3-phenyl-1-propanol 0.50.5 Ti(OPr)4 Ti (OPr) 4 0.50.5 EtherEther ZnZn 1.4 : 1.01.4: 1.0 1414 Amino-2-indanolAmino-2-indanol 0.50.5 Ti(OPr)4 Ti (OPr) 4 0.50.5 EtherEther ZnZn 1.25 : 1.01.25: 1.0 1515 cinchoninecinchonine 0.10.1 InCl3 InCl 3 0.10.1 EtherEther ZnZn 2.5 : 1.02.5: 1.0 1616 cinchonidinecinchonidine 0.10.1 InCl3 InCl 3 0.10.1 EtherEther ZnZn 2.5 : 1.02.5: 1.0 1717 QuinineQuinine 0.10.1 InCl3 InCl 3 0.10.1 EtherEther ZnZn 2.4 : 1.02.4: 1.0 1818 QuinidineQuinidine 0.10.1 InCl3 InCl 3 0.10.1 EtherEther ZnZn 2.6 : 1.02.6: 1.0 1919 cinchoninecinchonine 0.20.2 InCl3 InCl 3 0.10.1 EtherEther ZnZn 2.5 : 1.02.5: 1.0 2020 cinchonidinecinchonidine 0.20.2 InCl3 InCl 3 0.10.1 EtherEther ZnZn 2.4 : 1.02.4: 1.0 2121 QuinineQuinine 0.20.2 InCl3 InCl 3 0.10.1 EtherEther ZnZn 2.5 : 1.02.5: 1.0 2222 QuinidineQuinidine 0.20.2 InCl3 InCl 3 0.10.1 EtherEther ZnZn 2.6 : 1.02.6: 1.0 2323 cinchoninecinchonine 0.050.05 InCl3 InCl 3 0.050.05 EtherEther ZnZn 2.8 : 1.02.8: 1.0 2424 cinchonidinecinchonidine 0.050.05 InCl3 InCl 3 0.050.05 EtherEther ZnZn 2.8 : 1.02.8: 1.0 2525 QuinineQuinine 0.050.05 InCl3 InCl 3 0.050.05 EtherEther ZnZn 2.8 : 1.02.8: 1.0 2626 QuinidineQuinidine 0.050.05 InCl3 InCl 3 0.050.05 EtherEther ZnZn 2.6 : 1.02.6: 1.0

실시예 27. 4-(R)-[1-methyl(allyl)-azetidinone]의 제조 Ⅳ Example 27 Preparation of 4- (R)-[1-methyl (allyl) -azetidinone] IV

글로브 박스에서 둥근 바닥 플라스크에 4-아세톡시아제티디논(4-(R)-acetoxyasetidinone, AOSA) 200 ㎎(0.69 mmol), 퀴닌(quinine) 5.6 ㎎(2.5 mol%), 염화인듐 3.8 ㎎(2.5 mol%)을 넣고 아르곤 기체를 채워 밀봉하였다. 여기에 에테르 5㎖를 투입하여 반응온도를 25 ~ 35℃으로 유지하면서 크로틸 브롬 0.143 ㎖를 천천히 가하고, 30분 후에 아연 90.8 ㎎를 첨가하여 29℃에서 총 6시간 에 걸쳐 교반하되, 반응물은 TLC(ether : n-hexane = 2 : 1)로 확인하였다. In a round bottom flask, 4-acetoxyazetidinone (4- (R) -acetoxyasetidinone (AOSA) 200 mg (0.69 mmol), quinine 5.6 mg (2.5 mol%), indium chloride 3.8 mg (2.5) mol%) was added and sealed with argon gas. To this was added 5 ml of ether, slowly adding 0.143 ml of crotyl bromine while maintaining the reaction temperature at 25 to 35 ° C., and after 30 minutes, 90.8 mg of zinc was added and stirred at 29 ° C. for a total of 6 hours. It was confirmed that (ether: n-hexane = 2: 1).

상기 반응물에 다시 포화 염화암모늄 용액 20 ㎖ 및 에테르 20 ㎖를 가하고 2 ~ 3분 동안 교반한 다음, 분별 깔때기를 사용하여 물층을 제거하였다. 물층을 제거한 유기층에는 무수 소듐 셀페이트를 2 ~ 3 g 투입하고 15분간 교반하여 유기층 속에 남아있는 물층을 완전하게 제거한 후 글래스 필터로 여과시키고 유기용매 에테르로 세척하여 유기층을 감압 농축하였다. To the reaction was added 20 ml of saturated ammonium chloride solution and 20 ml of ether and stirred for 2 to 3 minutes, and then the water layer was removed using a separatory funnel. Anhydrous sodium sulphate was added to the organic layer from which the water layer was removed and stirred for 15 minutes to completely remove the water layer remaining in the organic layer, filtered through a glass filter, washed with an organic solvent ether, and concentrated under reduced pressure.

상기와 같은 과정으로 베타형 : 알파형의 비율이 3 : 1인 흰색의 4(R)-[1-methyl(allyl)-azetidinone]을 결정 형태로 수득하였다(수득율 95%). In the same manner as above, white 4 (R)-[1-methyl (allyl) -azetidinone] having a beta-alpha ratio of 3: 1 was obtained in crystalline form (yield 95%).

실시예 28. 4-(R)-[1-methyl(allyl)-azetidinone]의 제조 Ⅴ Example 28 Preparation of 4- (R)-[1-methyl (allyl) -azetidinone] V

상기 실시예 27와 동일한 방법으로 제조하되, 에테르 10 ㎖와 아연을 동시에 첨가하여 제조하고, 베타형 : 알파형의 비율이 3 : 1인 흰색의 4(R)-[1-methyl(allyl)-azetidinone]을 결정 형태로 수득하였다(수득율 95%). Prepared in the same manner as in Example 27, except that 10 ml of ether and zinc were added at the same time, and the beta-alpha-form ratio was 3: 1 in white 4 (R)-[1-methyl (allyl)-. azetidinone] was obtained in crystalline form (yield 95%).

실시예 29 ~ 36. 4-(R)-[1-methyl(allyl)-azetidinone]의 제조 Ⅵ Examples 29-36 Preparation of 4- (R)-[1-methyl (allyl) -azetidinone] VI

출발물질로서 0.69 mmol의 ASOA를 사용하여, 상기 실시예 27과 동일하게 반응을 진행시킨 결과, 표제 화합물이 하기 표 2와 같이 제조되었다.Using 0.69 mmol of ASOA as a starting material, the reaction was carried out in the same manner as in Example 27, whereby the title compound was prepared as shown in Table 2 below.

실시예Example 키랄 리간드Chiral ligand 당량(eq.)Equivalent (eq.) 루이스산Lewis Mountain 당량(eq.)Equivalent (eq.) 용매menstruum 전이금속Transition metal 반응온도(℃)Reaction temperature (℃) 비율(β:α)Ratio (β: α) 2929 cinchoninecinchonine 0.0250.025 InCl3 InCl 3 0.0250.025 EtherEther ZnZn 25~3025-30 2.2 : 12.2: 1 3030 cinchonidinecinchonidine 0.0250.025 InCl3 InCl 3 0.0250.025 EtherEther ZnZn 25~3025-30 3.0 : 13.0: 1 3131 quininequinine 0.0250.025 InCl3 InCl 3 0.0250.025 EtherEther ZnZn 25~3025-30 3.0 : 13.0: 1 3232 quinidinequinidine 0.0250.025 InCl3 InCl 3 0.0250.025 EtherEther ZnZn 25~3025-30 3.0 : 13.0: 1 3333 cinchonidinecinchonidine 0.050.05 InCl3 InCl 3 0.050.05 EtherEther ZnZn 25~3025-30 2.2 : 12.2: 1 3434 cinchoninecinchonine 0.01250.0125 InCl3 InCl 3 0.01250.0125 EtherEther ZnZn 25~3025-30 2.7 : 12.7: 1 3535 quinidinequinidine 0.01250.0125 InCl3 InCl 3 0.01250.0125 EtherEther ZnZn 25~3025-30 2.5 : 12.5: 1 3636 quininequinine 0.0250.025 InCl3 InCl 3 0.0250.025 EtherEther ZnZn 0~50-5 1.7 : 11.7: 1

실시예Example 37. 4-(R)-[1- 37. 4- (R)-[1- methylmethyl (( allylallyl )-)- azetidinoneazetidinone ]의 제조 Ⅶ Manufacturing of Ⅶ

글로브 박스에서 둥근 바닥 플라스크에 (3R,4R)-4-acetoxy-3-{(R)-l'[(t-butyldimethylsilyl)oxy]ethyl}-2-azetidinone 1.44 g(5.0 mmol), 신코니딘 (cinchonidine) 0.029 g(2.0 mol%), 염화 인듐 0.022 g(2.0 mol%)를 넣고 아르곤 기체를 채워 밀봉하였다. 여기에 에테르 42 ㎖를 투입하여 반응온도를 25 ~ 30℃ 으로 유지하면서 크로틸 브롬 1.0 ㎖(2.0 당량)를 천천히 가하고, 30분 후에 아연 0.65 g(2.0 당량)를 첨가하여 29℃에서 총 4시간 에 걸쳐 교반 하되, 반응의 진행여부는 TLC(ether : n-hexane = 2 : 1)로 확인하였다. 상기 반응물에 다시 포화 염화암모늄 용액 10 ㎖ 및 에테르 20 ㎖를 가지고 2번 세척하고 세척 후 Na2SO4 로 수분을 제거하여 유기층을 감압 농축하였다. 상기와 같은 과정으로 베타형 : 알파형의 비율이 3.2 : 1인 흰색의 생성물을 동일한 수율로 얻었다(수득율 95%).In a round bottom flask in a glove box, 1.44 g (5.0 mmol) of (3R, 4R) -4-acetoxy-3-{(R) -l '[(t-butyldimethylsilyl) oxy] ethyl} -2-azetidinone, cinconidine (cinchonidine) 0.029 g (2.0 mol%) and indium chloride 0.022 g (2.0 mol%) were added and sealed with argon gas. 42 ml of ether was added thereto, and 1.0 ml (2.0 equivalents) of crotyl bromide was slowly added while maintaining the reaction temperature at 25 to 30 ° C. After 30 minutes, 0.65 g (2.0 equivalents) of zinc was added thereto for a total of 4 hours at 29 ° C. Stirring over, the progress of the reaction was confirmed by TLC (ether: n-hexane = 2: 1). The reaction was washed twice with 10 ml of saturated ammonium chloride solution and 20 ml of ether. After washing, the organic layer was concentrated under reduced pressure by removing water with Na 2 SO 4 . In the same manner as above, a white product having a ratio of beta form to alpha form of 3.2: 1 was obtained in the same yield (yield 95%).

Claims (7)

4-아세톡시 아제티디논(4(R)-acetoxyazetidinone)을 출발물질로 하고, 키랄 리간드(Chiral Ligand), 전이금속, 루이스 산(Lewis acid)의 존재 하에서 크로틸화(crotylation) 시켜 하기의 화학식 1로 표현되는 4-(알크-2-에닐)-2-아제티디논을 제조하는 방법. 4-acetoxy azetidinone (4 (R) -acetoxyazetidinone) as a starting material, and crotylation (crotylation) in the presence of chiral ligand (Chiral Ligand), transition metal, Lewis acid (Formula 1 below) Method for preparing 4- (alk-2-enyl) -2-azetidinone represented by. [화학식 1][Formula 1] 단, 상기에서 R1, R2 는 각각 H, Me 이고 R3 는 수소원자 또는 하이드록실-보호 그룹이다.With the proviso that R 1 and R 2 Are each H, Me and R 3 is a hydrogen atom or a hydroxyl-protecting group. 제 1항에 있어서,The method of claim 1, 상기 키랄리간드는 신코닌(cinchonine), 신코니딘(cinchonidin), 퀴닌(quinine), 퀴니딘(quinidine), 노르에페드린(norephedrin), 2,2'-비스(디페닐포스피노)-1,1'-비나프틸(BINAP), (S)-(-)-아미노-3-페닐-1-프로판올{(S)-(-)-Amino-3-phenyl-1-propanol}, (R)-(-)-2-페닐글리시놀{(R)-(-)-2-Phenylglycinol}, 아미노-2-인단올(Amino-2-indanol), (S)-(+)-2-아미노-1-부탄올{(S)-(+)-Amino-1-butanol{, O-아세틸신코닌(O-acetylcinchonine), O-아세틸신코니딘(O-acetylcinchonidine), (R)-바이(2-나프톨){(R)-Bi(2-naphthol)}, (S)-바이(2-나프톨){(S)-Bi(2-naphthol)}, S-2-아미노프로판올(S-2-Aminopropanol), R-2-아미노프로판올(R-2-Aminopropanol), O-아세틸퀴닌(O-acetylquinine), O-아세틸퀴니딘(O-acetylquinidine)으로 이루어진 군에서 선택되는 것을 특징으로 하는 제조방법.The chiral ligands are cinchonine, cinchonidin, quinine, quinidine, norephedrin, 2,2'-bis (diphenylphosphino) -1,1 '-Binafyl (BINAP), (S)-(-)-amino-3-phenyl-1-propanol {(S)-(-)-Amino-3-phenyl-1-propanol}, (R)- (-)-2-phenylglycinol {(R)-(-)-2-Phenylglycinol}, amino-2-indanol, (S)-(+)-2-amino- 1-butanol {(S)-(+)-Amino-1-butanol {, O-acetylcinchonine, O-acetylcinchonidine, (R) -bi (2- Naphthol) {(R) -Bi (2-naphthol)}, (S) -bi (2-naphthol) {(S) -Bi (2-naphthol)}, S-2-aminopropanol ), R-2-aminopropanol (R-2-Aminopropanol), O-acetylquinine (O-acetylquinine), O-acetylquinidine (O-acetylquinidine) The production method characterized in that it is selected from the group consisting of. 제 1항에 있어서, 상기 전이금속은 아연(Zn) 또는 인듐(In)인 것을 특징으로 하는 제조방법.The method of claim 1, wherein the transition metal is zinc (Zn) or indium (In). 제 1항에 있어서, The method of claim 1, 상기 루이스산은 AgCl, PdCl, AgOTf, CuCl, CuCN, Cu(OAc)2, InCl3, PbBr2, GeCl3, Ti(OPr)4, ZnCl2, ZnBr2, CeCl3, Sc(OTf)3로 이루어진 군에서 선택되는 것을 특징으로 하는 제조방법.The Lewis acid is composed of AgCl, PdCl, AgOTf, CuCl, CuCN, Cu (OAc) 2 , InCl 3 , PbBr 2 , GeCl 3 , Ti (OPr) 4, ZnCl 2 , ZnBr 2, CeCl 3 , Sc (OTf) 3 Manufacturing method characterized in that selected from the group. 제 1항에 있어서,The method of claim 1, 상기 크로틸화 반응 용매는 석유에테르, 이소프로필에테르(IPE), 디에틸에테르, 디부틸에테르, t-부틸메틸에테르, 디옥산으로 이루어진 에테르(Ether) 용매; 테트라히드로퓨란(THF), 디알콕시알칸, N,N-디메틸 포름아마이드(N,N-Dimethyl foramide, DMF), 디메틸아세트아마이드, 디메틸술폰아마이드, 디클로로메탄(Dichloromethane, MC), 아세토니트릴(MeCN)로 이루어진 극성 용매; 벤젠, 톨루엔으로 이루어진 방향족 용매; 중에서 선택되는 1종 이상을 단독 또는 병행하여 사용하는 것을 특징으로 하는 제조방법.The crotylation reaction solvent is an ether solvent consisting of petroleum ether, isopropyl ether (IPE), diethyl ether, dibutyl ether, t-butylmethyl ether, dioxane; Tetrahydrofuran (THF), dialkoxyalkane, N, N-dimethyl foramide (DMF), dimethylacetamide, dimethylsulfonamide, dichloromethane (MC), acetonitrile (MeCN) A polar solvent consisting of; Aromatic solvents consisting of benzene and toluene; A production method characterized by using one or more selected from alone or in parallel. 제 1항에 있어서,The method of claim 1, 상기 반응은 0 ~ 50℃의 온도범위에서 진행되는 것을 특징으로 하는 제조방법. The reaction is characterized in that the proceeding in the temperature range of 0 ~ 50 ℃. 제 1항에 있어서,The method of claim 1, 상기 루이스산은 0.005 ~ 3 당량의 범위로 첨가되는 것을 특징으로 하는 제조방법. The Lewis acid is characterized in that the addition method in the range of 0.005 ~ 3 equivalents.
KR1020080026799A 2008-03-24 2008-03-24 Process for preparing alkenyl azetidinone intermediates for carbapenem KR100969217B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020080026799A KR100969217B1 (en) 2008-03-24 2008-03-24 Process for preparing alkenyl azetidinone intermediates for carbapenem

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020080026799A KR100969217B1 (en) 2008-03-24 2008-03-24 Process for preparing alkenyl azetidinone intermediates for carbapenem

Publications (2)

Publication Number Publication Date
KR20090101581A true KR20090101581A (en) 2009-09-29
KR100969217B1 KR100969217B1 (en) 2010-07-09

Family

ID=41359311

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020080026799A KR100969217B1 (en) 2008-03-24 2008-03-24 Process for preparing alkenyl azetidinone intermediates for carbapenem

Country Status (1)

Country Link
KR (1) KR100969217B1 (en)

Also Published As

Publication number Publication date
KR100969217B1 (en) 2010-07-09

Similar Documents

Publication Publication Date Title
US4778883A (en) 3-(CHFCH3)-azetidinone intermediates
DE69526443T2 (en) 2-SILYLOXY-TETRAHYDROTHIENOPYRIDINE, ITS SALT AND METHOD FOR THE PRODUCTION THEREOF
EP0331524B1 (en) Synthesis of trichostatins
JPH0557980B2 (en)
EP0167155B1 (en) Beta-lactam compound and preparing thereof
JPH032157B2 (en)
US20090023915A1 (en) Process for the Preparation of Faropenem
KR100969217B1 (en) Process for preparing alkenyl azetidinone intermediates for carbapenem
US5071966A (en) Process for preparing an enol silyl ether compound
DE68921306T2 (en) Process for the preparation of 4-acyloxy-2-azetidinone derivatives.
US4767853A (en) Synthesis of 1-(allyloxycarbonyl)-methyl-3-(hydroxyethyl)-4-beta-naphthoxythiocarbonylthio-2-azetidinones and hydroxy protected analogs thereof
US4511509A (en) 3-Alkylidine azetidine compound and their production
JP3954670B2 (en) Preparation of carbapenem antibiotic intermediates
JPH04368365A (en) Production of azetidinone derivative
US4709064A (en) β-N-substituted aminothiol ester and process for preparing the same
DE3408196C2 (en)
US4948885A (en) Synthesis of azetidinones
KR100959027B1 (en) Method for preparing penem intermediate using zinc compound as cocatalyst
US5053502A (en) Anhydro penicillin derivatives
AT393839B (en) Stereocontrolled process for the preparation of novel penem compounds
DE69618570T2 (en) METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE TRANS-VINYL SULFIDAL ALCOHOLS
US5075438A (en) Synthesis of azetidinones
KR20040099963A (en) Chiral 2-azetidinone compounds, process and use thereof
JP2012506843A (en) 1,3 imidazolidine derivatives and their use in the production of carbapenem
US4876338A (en) Synthesis of azetidinones using CuCl

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20080324

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100216

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20100701

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20100702

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20100705

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20130906

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20130906

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20140414

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20140414

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20150428

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20150428

Start annual number: 6

End annual number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20170609